Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists

References

• Dudinskaya EN, Tkacheva ON, Bazaeva EV, et al. New possibilities of using moxonidin for blood pressure control in female patients with osteopenia. Kardiologiya. 2018;58:36–45. doi:10.18087/cardio.2508
   PubMed Web of Science ®Google Scholar
• Tkacheva O, Dudinskaya EN, Bazaeva EV. P3205 New features of use of moxonidine as telomerase activator. Eur Heart J. 2018;39(suppl_1):ehy563–P3205. doi:10.1093/eurheartj/ehy563.P3205
   Google Scholar
• Sokoluk TV, Gorbenko NI, Podgayniy DG, Merzlikin SI. Experimental investigations of the influence of the pharmaceutical composition with the two antidiabetic agents on some manifestations of metabolic syndrome X. Farmatsevti Zhurnal. 2009;1:110–114.
   Google Scholar
• Chen S, Gan D, Lin S, et al. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics. 2022;12(6):2722–2740. doi:10.7150/thno.71360
   PubMed Web of Science ®Google Scholar
• Cobos-Puc L, Aguayo-Morales H. cardiovascular effects mediated by imidazoline drugs: an update. Cardiov Haematol Disord Drug Targ. 2019;19(2):95–108. doi:10.2174/1871529X18666180629170336
   PubMedGoogle Scholar
• Ernsberger P. The I1‐Imidazoline receptor and its cellular signaling pathways a. Ann NY Acad Sci. 1999;881(1):35–53. doi:10.1111/j.1749-6632.1999.tb09339.x
   PubMedGoogle Scholar
• Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs? J Psychiatry Neurosci. 2003;28(6):409.
   PubMed Web of Science ®Google Scholar
• Takada K, Hayashi Y, Kamibayashi T, et al. The involvement of pertussis toxin‐sensitive G proteins in the post receptor mechanism of central I1‐imidazoline receptors. Br J Pharmacol. 1997;120(8):1575–1581. doi:10.1038/sj.bjp.0701090
   PubMed Web of Science ®Google Scholar
• Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline receptor system: the past, the present, and the future. Pharmacol Rev 2020;721:50–79. doi:10.1124/pr.118.016311
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Liu Y, Chen H, Gong J. Activation of imidazoline I1 receptor by moxonidine regulates the progression of liver fibrosis in the Nrf2-dependent pathway. Biomed Pharmacother. 2017;90:821–834. doi:10.1016/j.biopha.2017.04.025
   PubMed Web of Science ®Google Scholar
• Tesfai J, Crane L, Baziard-Mouysset G, Edwards LP. Novel I1-Imidazoline agonist S43126 augment insulin secretion in Min6 cells. J Diab Metabol. 2012;3(3). doi:10.4172/2155-6156.1000183
   PubMedGoogle Scholar
• Weiss M, Bouchoucha S, Aiad F, et al. Imidazoline-like drugs improve insulin sensitivity through peripheral stimulation of adiponectin and AMPK pathways in a rat model of glucose intolerance. Am J Physiol Endocrinol Metab. 2015;309(2):E95–E104. doi:10.1152/ajpendo.00021.2015
   PubMed Web of Science ®Google Scholar
• Fellmann L, Nascimento AR, Tibiriça E, Bousquet P. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther. 2013;137(3):331–340. doi:10.1016/j.pharmthera.2012.11.004
   PubMed Web of Science ®Google Scholar
• Kawamoto S, Hirakata H, Sugita N, Fukuda K. Bidirectional effects of dexmedetomidine on human platelet functions in vitro. Eur J Pharmacol. 2015;766:122–128. doi:10.1016/j.ejphar.2015.09.049
   PubMed Web of Science ®Google Scholar
• Yang PS, Wu HT, Chung HH, et al. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg’s Arch Pharmacol. 2012;385:51–56. doi:10.1007/s00210-011-0691-1
   Google Scholar
• Parini A, Moudanos CG, Pizzinat N, Lanier SM. The elusive family of imidazoline binding sites. Trends Pharmacol Sci. 1996;17(1):13–16. doi:10.1016/0165-6147(96)81564-1
   PubMed Web of Science ®Google Scholar
• Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos ARS, Rodrigues ALS. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport. 2002;13(4):387–391. doi:10.1097/00001756-200203250-00005
   PubMed Web of Science ®Google Scholar
• Abás S, Erdozain AM, Keller B, et al. Neuroprotective effects of a structurally new family of high affinity imidazoline I2 receptor ligands. ACS Chem Neurosci. 2017;8(4):737–742. doi:10.1021/acschemneuro.6b00426
   PubMed Web of Science ®Google Scholar
• Tyacke RJ, Myers JF, Venkataraman A, et al. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. J Nucl Med. 2018;59(10):1597–1602. doi:10.2967/jnumed.118.208009
   PubMed Web of Science ®Google Scholar
• Parker CA, Nabulsi N, Holden D, et al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. J Nucl Med. 2014;55(5):838–844. doi:10.2967/jnumed.113.131854
   PubMed Web of Science ®Google Scholar
• Boronat MA, Olmos G, García‐Sevilla JA. Attenuation of tolerance to opioid‐induced antinociception and protection against morphine‐induced decrease of neurofilament proteins by idazoxan and other I2‐imidazoline ligands. Br J Pharmacol. 1998;125(1):175–185. doi:10.1038/sj.bjp.0702031
   PubMed Web of Science ®Google Scholar
• Sánchez‐Blázquez P, Boronat MA, Olmos G, García‐Sevilla JA, Garzón J. Activation of I2‐imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol. 2000;130(1):146–152. doi:10.1038/sj.bjp.0703294
   PubMed Web of Science ®Google Scholar
• Gentili F, Cardinaletti C, Carrieri A, et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur J Pharmacol. 2006;553(1–3):73–81. doi:10.1016/j.ejphar.2006.09.031
   PubMed Web of Science ®Google Scholar
• Thorn DA, Zhang Y, Peng BW, Winter JC, Li JX. Effects of imidazoline I2 receptor ligands on morphine-and tramadol-induced antinociception in rats. Eur J Pharmacol. 2011;670(2–3):435–440. doi:10.1016/j.ejphar.2011.09.173
   PubMed Web of Science ®Google Scholar
• Sampson C, Zhang Y, Del Bello F, Li J-X. Effects of imidazoline I2 receptor ligands on acute nociception in rats. Neuroreport. 2012;23(2):73–77. doi:10.1097/WNR.0b013e32834e7db3
   PubMed Web of Science ®Google Scholar
• Li JX, Zhang Y. Imidazoline I2 receptors: target for new analgesics? Eur J Pharmacol. 2011;658(2–3):49–56. doi:10.1016/j.ejphar.2011.02.038
   PubMed Web of Science ®Google Scholar
• Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30(1):103–114. doi:10.1016/0304-3959(87)90088-1
   PubMed Web of Science ®Google Scholar
• Thorn DA, Zhang Y, Li J. Effects of the imidazoline I2 receptor agonist 2‐BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats. Br J Pharmacol. 2016;173(8):1363–1372. doi:10.1111/bph.13435
   PubMed Web of Science ®Google Scholar
• Ferrari F, Fiorentino S, Mennuni L, et al. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res;2011. 111–125. doi:10.2147/JPR.S18353
   PubMedGoogle Scholar
• Siemian JN, Li J, Zhang Y, Li JX. Interactions between imidazoline I 2 receptor ligands and Acetaminophen in adult male rats: antinociception and schedule-controlled responding. Psychopharmacology. 2016;233:873–882. doi:10.1007/s00213-015-4166-9
   PubMed Web of Science ®Google Scholar
• Meregalli C, Ceresa C, Canta A, et al. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res;2012. 151–167. doi:10.2147/JPR.S32122
   PubMedGoogle Scholar
• Lanza M, Ferrari F, Menghetti I, Tremolada D, Caselli G. Modulation of imidazoline I 2 binding sites by CR 4056 relieves postoperative hyperalgesia in male and female rats. Br J Pharmacol. 2014;171(15):3693–3701. doi:10.1111/bph.12728
   PubMed Web of Science ®Google Scholar
• Eglen RM, Hudson AL, Kendall DA, et al. Seeing through a glass darkly’: casting light on imidazolineI’sites. Trends Pharmacol Sci. 1998;19(9):381–390. doi:10.1016/S0165-6147(98)01244-9
   PubMed Web of Science ®Google Scholar
• Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des. 2001;7(14):1413–1431. doi:10.2174/1381612013397366
   PubMed Web of Science ®Google Scholar
• Cerasi E, Effendic S, Luft R. Role of adrenergic receptors in glucose-induced insulin secretion in man. Lancet. 1969;294:7615):301–302. doi:10.1016/S0140-6736(69)90059-2
   Google Scholar
• Chan SL, Brown CA, Scarpello KE, Morgan NG. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1‐and I2‐sites. Br J Pharmacol. 1994;112(4):1065–1070. doi:10.1111/j.1476-5381.1994.tb13191.x
   PubMed Web of Science ®Google Scholar
• Berdeu D, Gross R, Puech R, Loubatières-Mariani MM, Bertrand G. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur J Pharmacol. 1995;275(1):91–98. doi:10.1016/0014-2999(94)00757-X
   PubMed Web of Science ®Google Scholar
• Ishida‐Takahashi A, Horie M, Tsuura Y, Ishida H, Ai T, Sasayama S. Block of pancreatic ATP‐sensitive K+ channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline. Br J Pharmacol. 1996;117(8):1749–1755. doi:10.1111/j.1476-5381.1996.tb15349.x
   PubMed Web of Science ®Google Scholar
• Proks P, Ashcroft FM. Phentolamine block of KATP channels is mediated by Kir6. 2. Proc Natl Acad Sci. 1997;94(21):11716–11720. doi:10.1073/pnas.94.21.11716
   PubMed Web of Science ®Google Scholar
• Monks LK, Cosgrove KE, Dunne MJ, Ramsden CA, Morgan NG, Chan SL. Affinity isolation of imidazoline binding proteins from rat brain using 5-amino-efaroxan as a ligand. FEBS Lett. 1999;447(1):61–64. doi:10.1016/S0014-5793(99)00264-1
   PubMed Web of Science ®Google Scholar
• Ferrer-Montiel AV, Merino JM, Planells-Cases R, Sun W, Montal M. Structural determinants of the blocker binding site in glutamate and NMDA receptor channels. Neuropharmacology. 1998;37(2):139–147. doi:10.1016/S0028-3908(98)00007-0
   PubMed Web of Science ®Google Scholar
• Roberg K, Johansson U, Öllinger K. Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress. Free Radic Biol Med. 1999;27(11–12):1228–1237. doi:10.1016/S0891-5849(99)00146-X
   PubMed Web of Science ®Google Scholar
• Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P. Pharmacology of moxonidine, an I1-imidazoline receptor agonist. J Cardiov Pharmacol. 1996;27:S26–S37. doi:10.1097/00005344-199627003-00005
   PubMed Web of Science ®Google Scholar
• Yamakura T, Shimoji K. Subunit-and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol. 1999;59(3):279–298. doi:10.1016/S0301-0082(99)00007-6
   PubMed Web of Science ®Google Scholar
• Basile L, Pappalardo M, Guccione S, Milardi D, Ramsay RR. Computational comparison of imidazoline association with the I2 binding site in human monoamine oxidases. J Chem Inf Model. 2014;54(4):1200–1207. doi:10.1021/ci400346k
   PubMed Web of Science ®Google Scholar
• Nikolic K, Veljkovic N, Gemovic B, Srdic-Rajic T, Agbaba D. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study. Comb Chem High Through Screen. 2013;16(4):298–319. doi:10.2174/1386207311316040004
   PubMed Web of Science ®Google Scholar
• Tong L, Cui D, Zeng J. Topical bendazol inhibits experimental myopia progression and decreases the ocular accumulation of HIF‐1α protein in young rabbits. Ophthalmic Physiol Opt. 2020;40(5):567–576. doi:10.1111/opo.12717
   PubMed Web of Science ®Google Scholar
• Abramets II, Zayka TO, Evdokimov DV, Kuznetsov YV, Sidorova YV. Researches of the imidazole and indole derivatives cerebroprotective activity and its impact on effects of antidepressants. Pharmacokin Pharmacod. 2020;(1):18–24. doi:10.37489/2587-7836-2020-1-18-24
   Google Scholar
• Brishty SR, MdJ H, Khandaker MU, Faruque MRI, Osman H, Rahman SMA. A comprehensive account on recent progress in pharmacological activities of benzimidazole derivatives. Front Pharmacol. 2021;12:762807. doi:10.3389/fphar.2021.762807
   PubMed Web of Science ®Google Scholar
• Atilgan E, Hu J. Improving protein docking using sustainable genetic algorithms. Int J Compu Inoform Sys Ind Manag App. 2011;3:248–255.
   Google Scholar
• Štekláč M, Zajaček D, Bučinský L. 3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found? J Mol Struct. 2021;1245:130968. doi:10.1016/j.molstruc.2021.130968
   PubMed Web of Science ®Google Scholar
• Land H, Humble MS. YASARA: a tool to obtain structural guidance in biocatalytic investigations. Prot Engine. 2018;43–67. doi:10.1007/978-1-4939-7366-8_4
   Google Scholar
• Belyaeva J, Zlobin A, Maslova V, Golovin A. Modern non-polarizable force fields diverge in modeling the enzyme–substrate complex of a canonical serine protease. Phys Chem Chem Phys. 2023;25(8):6352–6361. doi:10.1039/D2CP05502C
   PubMed Web of Science ®Google Scholar
• Hsu KC, Chen YF, Lin SR, Yang JM. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinf. 2011;12(S1):S33. doi:10.1186/1471-2105-12-S1-S33
   PubMedGoogle Scholar
• Azad I, Khan T, Maurya AK, Irfan Azad M, Mishra N, Alanazi AM. Identification of severe acute respiratory syndrome coronavirus‐2 inhibitors through in silico structure‐based virtual screening and molecular interaction studies. J Mol Recog. 2021;34(10):e2918. doi:10.1002/jmr.2918
   PubMed Web of Science ®Google Scholar
• Velavan S, Karnan R, Kanivalan N. A comparative study on In silico software’s in statistical relation to molecular docking scores. Asian J Innov Res. 2020;5(2):1–5.
   Google Scholar
• Ahmad R. Steroidal glycoalkaloids from Solanum nigrum target cytoskeletal proteins: an in silico analysis. PeerJ. 2019;7:e6012. doi:10.7717/peerj.6012
   PubMed Web of Science ®Google Scholar
• Yuan S, Chan HS, Hu Z. Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci. 2017;7(2):e1298. doi:10.1002/wcms.1298
   Web of Science ®Google Scholar
• Yuan S, Chan HS, Filipek S, Vogel H. PyMOL and Inkscape bridge the data and the data visualization. Structure. 2016;24(12):2041–2042. doi:10.1016/j.str.2016.11.012
   PubMed Web of Science ®Google Scholar
• Sandy S. In silico molecular docking of the antimalarial flavonoid compound macaranga (macaranga tanarius) against the PfDHFR Enzyme. Curr Trends Biotechnol Pharm. 2023;17(3):929–936.
   Google Scholar
• Mahboobi M, Salmanian AH, Sedighian H, Bambai B. Molecular Modeling and Optimization of Type II E. coli l-Asparginase Activity by in silico Design and in vitro Site-directed Mutagenesis. Prot J. 2023;2023:1–11.
   Google Scholar
• Kuvarina AE, Sukonnikov MA, Rogozhin EA, et al. Formation of various antimicrobial peptide emericellipsin isoforms in emericellopsos alkalina under different cultivation conditions. Appl Biochem Microbiol. 2023;59(2):160–167. doi:10.1134/S0003683823020060
   Web of Science ®Google Scholar
• Nishanth S, Chikunov AS, Thankappan S, Taran OP, Parmon VN, Uthandi S. Lignin derived aromatic monomers from birch wood by laccase (LccH) pretreatment and Ru/C catalyst: a two-pot approach for sustainable biorefineries. Biomass Convers Biorefin. 2022;2022:1–16.
   Google Scholar
• Abdel-karim AM, Shahen S, Elsisi DM, Hyba AM, El-Shamy OA. Experimental and theoretical studies of corrosion resistance enhancement of carbon steel in 1 M HCl by quinoxalinosulfonamide hybrid-bearing theophylline moiety. J Bio- Tribo-Corros. 2022;8(3):70. doi:10.1007/s40735-022-00666-0
   Google Scholar
• Ezzat A, Mohamed MBI, Mahmoud AM, Farag RS, El-Tabl AS, Ragab A. Synthesis, spectral characterization, antimicrobial evaluation and molecular docking studies of new Cu (II), Zn (II) thiosemicarbazone based on sulfonyl isatin. J Mol Struct. 2022;1251:132004. doi:10.1016/j.molstruc.2021.132004
   Web of Science ®Google Scholar
• Nasser M, Alyamani AA, Daou A, et al. Influence of the extraction solvent and of the altitude on the anticancer activity of Lebanese eucalyptus camaldulensis extract alone or in combination with low dose of cisplatin in A549 human lung adenocarcinoma cells. Processes. 2022;10(8):1461. doi:10.3390/pr10081461
   Web of Science ®Google Scholar
• Sarter M. Cooperative change in the internal dynamics of streptavidin caused by biotin binding. J Phys Chem A. 2023;127(14):3241–3247. doi:10.1021/acs.jpcb.3c00427
   Web of Science ®Google Scholar
• Yamada S, Kataoka M, Yoshida K, et al. Development of hydrogen-bonded dimer-type photoluminescent liquid crystals of fluorinated tolanecarboxylic acid. Crystals. 2022;13(1):25. doi:10.3390/cryst13010025
   Web of Science ®Google Scholar
• Vasil’ev SG, Panicheva KV. The self-di usion of 128-arm star-shaped polydimethylsiloxanes with a dendritic branching center. In: Magnetic Resonance and Its Applications. Spinus-2022; 2022:176–177.
   Google Scholar
• Nekkalapudi AR, Veldi VG, Pippalla S. A novel RP-HPLC method for estimating fulvestrant, benzoyl alcohol, and benzyl benzoate in injection formulation. Am J Anal Chem. 2022;13(7):229–240. doi:10.4236/ajac.2022.137016
   Google Scholar
• Slassi S, Aarjane M, Amine A. Synthesis, spectroscopic characterization (FT-IR, NMR, UV-Vis), DFT study, antibacterial and antioxidant in vitro investigations of 4, 6-bis ((E)-1-((3-(1H-imidazol-1-yl) propyl) imino) ethyl) benzene-1, 3-diol. J Mol Struct. 2022;1255:132457. doi:10.1016/j.molstruc.2022.132457
   Web of Science ®Google Scholar
• Ramirez H, Dominguez J, Fernandez-Moreira E, Rodrigues J, Rodriguez M, Charris JE. Synthesis of 4-Benzylsulfanyl and 4-benzylsulfonyl chalcones. biological evaluation as antimalarial agents. Vaccine. 2022;3:4.
   Google Scholar
• Jena GB, Chavan S. Implementation of good laboratory practices (GLP) in basic scientific research: translating the concept beyond regulatory compliance. Regul Toxicol Pharmacol. 2017;89:20–25. doi:10.1016/j.yrtph.2017.07.010
   PubMed Web of Science ®Google Scholar
• Olsson IAS, da SSP, Townend D, Sandøe P. Protecting animals and enabling research in the European Union: an overview of development and implementation of directive 2010/63/EU. ILAR Jl. 2017;57(3):347–357. doi:10.1093/ilar/ilw029
   Web of Science ®Google Scholar
• Mustafakulov M, Kimsanova N, Hamdamova N, et al. Determination of antioxidant properties of l-cysteine in the liver of alloxan diabetes model rats. Internat J Contemp Sci Tech Res. 2023;2023:47–54.
   Google Scholar
• Akoko S, Aleme BM, Uahomo PO. The effect of addition of extracts of Vernonia amygdalina and Moringa oleifera in the nutrition of alloxan-induced diabetic Wistar Rats. Inter J Phar Res Health Sci. 2022;10(4):3455–3462.
   Google Scholar
• Etuk EU. Animals models for studying diabetes mellitus. Agric Biol J North Am. 2010;1(2):130–134.
   Google Scholar
• Katz LB, Stewart L, Guthrie B, Cameron H. Patient satisfaction with a new, high accuracy blood glucose meter that provides personalized guidance, insight, and encouragement. J Diabet Sci Technol. 2020;14(2):318–323. doi:10.1177/1932296819867396
   PubMedGoogle Scholar
• Maraš N, Kočevar M. Boric acid‐catalyzed direct condensation of carboxylic acids with benzene‐1, 2‐diamine into benzimidazoles. Helvetica Chim Acta. 2011;94(10):1860–1874. doi:10.1002/hlca.201100064
   Web of Science ®Google Scholar